Los Angeles Capital Management & Equity Research Inc. continued to hold its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,597 shares of the company’s stock at the end of the third quarter. Los Angeles Capital Management & Equity Research Inc. owned 0.11% of Anika Therapeutics worth $794,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of ANIK. Victory Capital Management Inc. boosted its position in shares of Anika Therapeutics by 34.9% in the third quarter. Victory Capital Management Inc. now owns 2,101 shares of the company’s stock worth $101,000 after buying an additional 543 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of Anika Therapeutics by 14.1% in the second quarter. Teacher Retirement System of Texas now owns 2,037 shares of the company’s stock worth $109,000 after buying an additional 252 shares during the last quarter. BlackRock Inc. boosted its position in shares of Anika Therapeutics by 99.0% in the second quarter. BlackRock Inc. now owns 2,032 shares of the company’s stock worth $109,000 after buying an additional 1,011 shares during the last quarter. Mason Street Advisors LLC purchased a new position in shares of Anika Therapeutics during the second quarter worth about $150,000. Finally, Municipal Employees Retirement System of Michigan boosted its position in shares of Anika Therapeutics by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,180 shares of the company’s stock worth $152,000 after buying an additional 50 shares during the last quarter. 76.01% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) traded down 0.18% during trading on Friday, reaching $50.03. The company’s stock had a trading volume of 64,172 shares. The stock has a market cap of $731.59 million, a P/E ratio of 21.46 and a beta of 1.75. The stock’s 50-day moving average is $48.28 and its 200-day moving average is $48.10. Anika Therapeutics Inc. has a 12-month low of $35.07 and a 12-month high of $54.96.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, October 26th. The company reported $0.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.12. Anika Therapeutics had a net margin of 33.64% and a return on equity of 17.21%. The firm had revenue of $25.79 million for the quarter, compared to the consensus estimate of $26.60 million. During the same period last year, the firm earned $0.55 earnings per share. The company’s quarterly revenue was up 8.9% on a year-over-year basis. Equities research analysts anticipate that Anika Therapeutics Inc. will post $2.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Anika Therapeutics Inc. (ANIK) Stake Held by Los Angeles Capital Management & Equity Research Inc.” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright laws. The correct version of this report can be accessed at http://www.watchlistnews.com/anika-therapeutics-inc-anik-stake-held-by-los-angeles-capital-management-equity-research-inc/1060818.html.

Separately, Zacks Investment Research cut Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 11th.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.

5 Day Chart for NASDAQ:ANIK

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.